Vertex Pharmaceuticals Incorporated

VRTX Pharmaceutical Preparations · Nasdaq

Market statistics

Annualised volatility 28.8%
Beta vs SPY 0.53
Market correlation 0.234
Rate sensitivity -0.31
Volatility sensitivity -0.29
Traded per day $599.0M

Measured from daily returns over the past year. That is not the same estimator as the beta quoted on most finance sites, which is usually five years of monthly returns, and in a market where single stocks move on their own news the daily figure comes out materially lower. Over this window the average large-cap correlation to the index is far below its long-run level: a low number here is a statement about the last twelve months, not a claim that the security is uncorrelated with the market in general.

As filed with the SEC twelve months to 2025-12-31 · balance sheet 2026-03-31

Revenue $12.00B
Operating income $4.17B
Net income $3.95B
Diluted EPS $15.32
Total assets $26.48B
Total liabilities $7.12B
Shareholders’ equity $19.36B
Cash & equivalents $5.49B
Shares outstanding 254.2M

Short selling — three different measurements

Shares short 4.1M
Days to cover 3.1
Change vs prior +5.2%
Short share of volume 62.2%
Largest fail balance 44,303
Dates with a fail balance 14

These measure different things and are routinely confused. Shares short is an outstanding position, reported twice monthly (settlement 2026-08-14). Short share of volume counts sell-side transactions flagged short each day, most of which is market-maker hedging closed the same session — the market-wide median is around half. Fail balances are shares that did not settle on time; the SEC states these are cumulative balances whose age cannot be determined, and they are not evidence of naked short selling.

Ownership

Institutions reporting a position 1,677
Reported value $98.10B

Largest reported holdersamong the managers stored here

ManagerReported valueShares
Capital World Investors $11.33B 25,368,124
BlackRock, Inc. $10.70B 23,969,517
Capital Research Global Investors $9.43B 21,125,964
VANGUARD CAPITAL MANAGEMENT LLC $7.37B 16,512,810
STATE STREET CORP $5.24B 11,730,139
GEODE CAPITAL MANAGEMENT, LLC $2.73B 6,139,621
Capital International Investors $2.29B 5,126,077
LOOMIS SAYLES & CO L P $1.79B 4,003,821

On the public record

Moves most like

Ticker1-year correlationVolatility vs VRTX
IBB iShares Biotechnology ETF 0.665 0.76×
FBT First Trust Amex Biotech Index Fund 0.594 0.76×
PPH VanEck Pharmaceutical ETF 0.558 0.65×
IHE iShares U.S. Pharmaceutical ETF 0.551 0.63×
PINK Simplify Health Care ETF 0.539 0.64×
AMGN Amgen Inc. 0.513 1.03×
XBI State Street SPDR S&P Biotech ETF 0.493 0.97×
ABBV AbbVie Inc. 0.476 0.93×

What is on this page

Everything this site holds about one security, from sources that are all public record. The figures come from different places and mean different things, so each block says where it came from.

What is deliberately absent

No price, no chart, no market capitalisation, no valuation ratio. The daily price history behind the statistics above is licensed from a commercial vendor and cannot be republished — and publishing a market cap alongside a share count would hand the price straight back. Every number here is either a public filing or a statistic from which the underlying series cannot be reconstructed.

Coverage

US securities trading at least $1 million a day with three years of history. Sections appear only where there is something to show: a fund has no income statement, most companies have no activist stake, and only a few dozen listed companies hold material federal contracts.